v3.25.2
Stockholders’ Equity
6 Months Ended
Jun. 30, 2025
Equity [Abstract]  
Stockholders’ Equity

Note 7. Stockholders’ Equity

 

Common Stock

 

On January 18, 2023 and February 18, 2023, the Company issued to Charles Hyatt, an aggregate of 11,428,570 units, with each unit consisting of one share of common stock and a two-year warrant to purchase one share of common stock at an exercise price of $0.0175 per share in consideration of $200,000.

 

On March 31, 2023, the Company issued 61,204 shares of common stock to Robert Carmichael for payment of interest on the convertible demand note for the three months ending March 31, 2023. The fair value of these shares was $1,336.

 

On March 31, 2023, the Company issued an aggregate of 137,000 shares of common stock to the holders of convertible notes for payment of interest for the three months ending December 31, 2022. The fair value of these shares was $7,000.

 

On June 30, 2023, the Company issued 61,205 shares of common stock to Robert Carmichael for payment of interest on the convertible demand note for the three months ending June 30, 2023. The fair value of these shares was $1,326.

 

On June 30, 2023, the Company issued an aggregate of 137,000 shares of common stock to the holders of convertible notes for payment of interest for the three months ending June 30, 2023. The fair value of these shares was $7,000.

 

On September 30, 2023, the Company issued 61,205 shares of common stock to Robert Carmichael for payment of interest on the convertible demand note for the three months ending September 30, 2023. The fair value of these shares was $1,326.

 

On September 30, 2023, the Company issued an aggregate of 137,000 shares of common stock to the holders of convertible notes for payment of interest for the three months ending September 30, 2023. The fair value of these shares was $7,000.

 

On December 31, 2023, the Company issued 61,677 shares of common stock to Robert Carmichael for payment of interest on the convertible demand note for the three months ending December 31, 2023. The fair value of these shares was $1,287.

 

On December 31, 2023, the Company issued an aggregate of 136,527 shares of common stock to the holders of convertible notes for payment of interest for the three months ending December 31, 2023. The fair value of these shares was $7,000.

 

On March 31, 2024, the Company issued 61,677 shares of common stock to Robert Carmichael for payment of interest on the convertible demand note for the three months ending March 31, 2024. The fair value of these shares was $4,007.

 

On March 31, 2024, the Company issued an aggregate of 136,527 shares of common stock to the holders of convertible notes for payment of interest for the three months ending March 31, 2024. The fair value of these shares was $7,000.

 

On June 30, 2024, the Company issued 123,354 shares of common stock to Robert Carmichael for payment of interest on the convertible demand note for the three months ending June 30, 2024. The fair value of these shares was $2,672.

 

On June 30, 2025, the Company issued an aggregate of 136,527 shares of common stock to the holders of convertible notes for payment of interest for the three months ending June 30, 2025. The fair value of these shares was $7,000.

 

On August 15, 2024 the Company issued 850,000 shares of common stock to the holders of convertible notes for payment of professional services. The fair market value of these shares was $8,500.

 

On September 30, 2024, the Company issued an aggregate of 136,527 shares of common stock to the holders of convertible notes for payment of interest for the three months ending September 30, 2024. The fair value of these shares was $7,000.

 

On December 9, 2024, the Company issued 8,241,759 shares to Blake Carmichael as compensation related to a salary reduction. The fair market value of these shares was $60,000.

 

 

On December 31, 2024, the Company issued an aggregate of 136,527 shares of common stock to the holders of convertible notes for payment of interest for the three months ending December 31, 2024. The fair value of these shares was $7,000.

 

On March 31,2025, the Company issued an aggregate of 136,527 shares of common stock to the holders of convertible notes for payment of interest for the three months ending March 31 2025,. The fair value of these shares was $7,000.

 

On June 30,2025, the Company issued an aggregate of 136,527 shares of common stock to the holders of convertible notes for payment of interest for the three months ending June 30, 2025,. The fair value of these shares was $7,000.

 

Preferred Stock

 

During the second quarter of 2010, the holders of the majority of the Company’s outstanding shares of common stock approved an amendment to the Company’s Articles of Incorporation authorizing the issuance of 10,000,000 shares of blank check preferred stock. The blank check preferred stock as authorized has such voting powers, designations, preferences, limitations, restrictions and relative rights as may be determined by the Board of Directors of the Company from time to time in accordance with the provisions of the Florida Business Corporation Act. In April 2011, the Board of Directors designated 425,000 shares as Series A Convertible Preferred Stock. Each share of Series A Convertible Preferred Stock is convertible into a share of the Company’s common stock at any time at the option of the holder at a conversion price of $18.23 per share. Holders of shares of Series A Convertible Preferred Stock are entitled to 250 votes for each share held. The Company’s common stock and Series A Convertible Preferred Stock vote together on any matters submitted to our shareholders. As of June 30, 2025, and December 31, 2024, 425,000 shares of Series A Convertible Preferred Stock are issued and outstanding and are owned by Robert Carmichael.

 

Equity Incentive Plan

 

On May 26, 2021 the Company adopted an Equity Incentive Plan (the “Plan”). Under the Plan, stock options may be granted to employees, directors, and consultants in the form of incentive stock options or non-qualified stock options, stock purchase rights, time vested and/performance invested restricted stock, and stock appreciation rights and unrestricted shares may also be granted under the Plan. 25,000,000 shares are reserved for issuance under the Plan. The term of the Plan is ten years.

 

The Company also issued options outside of the Plan that were not approved by the security holders. These options may be granted to employees, directors, and consultants in the form of incentive stock options or non-qualified stock options.

 

Equity Compensation Plan Information as of June 30, 2025:

 

   Number of securities
to be issued upon exercise of outstanding options, warrants and
rights
(a)
   Weighted – average exercise price of outstanding options,
warrants and rights
(b)
   Number of securities remaining available for future issuances under equity
compensation plans (excluding securities reflected in column
(a) (c)
 
Equity Compensation Plans Approved by Security Holders   3,150,000   $0.0399    21,680,882 
Equity Compensation Plans Not Approved by Security Holders   37,801,503    0.0195     
Total   40,951,503   $0.0297    21,680,882 

 

Options

 

The Company has issued options to purchase approximately 67,314,637 shares of its common stock at an weighted average exercise price of $0.0298 with a fair value of approximately $37,000. For the three months ended June 30, 2025, and the year ended December 31, 2023, the Company issued no options to purchase shares.

 

For the six months ended June 30, 2025 and 2024, the Company recognized an expense of $0. and $12,423, respectively, of non-cash compensation expense (included in General and Administrative expense in the accompanying Consolidated Statement of Operations) determined by application of a Black-Scholes option pricing model with the following inputs: exercise price, dividend yields, risk-free interest rate, and expected annual volatility. As of June 30, 2025, the Company had $32,500 of unrecognized pre-tax non-cash compensation expense related to performance based options to purchase shares, which the Company expects to recognize, based on a weighted-average period of .88 years. The Company uses straight-line amortization of compensation expense over the requisite service period for time-based options. For performance-based options the Company evaluates the likelihood of a vesting qualification being met, and will establish the expense based on that evaluation. The maximum contractual term of the Company’s stock options is 5 years. The Company recognizes forfeitures and expirations as they occur. Options to purchase 37,801,503 shares of common stock have vested as of June 30, 2025.

 

 

The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock option awards and warrant issuances. The calculation of the fair value of the awards using the Black-Scholes option-pricing model is affected by the Company’s stock price on the date of grant as well as assumptions regarding the following:

 

   Six Months ended June 30, 
   2025   2024 
Expected volatility   172.0% - 346.4%   172.0346.4%
Expected term   1.55.0 Years    1.55.0 Years 
Risk-free interest rate   0.16% - 4.64%   0.16% - 4.64%
Forfeiture rate   0.17%   0.17%

 

The expected volatility was determined with reference to the historical volatility of the Company’s common stock. The Company uses historical data to estimate option exercise and employee termination within the valuation model. The expected term of options granted represents the period of time that options granted are expected to be outstanding. The risk-free interest rate for periods within the contractual life of the option is based on the U.S. Treasury rate in effect at the time of grant.

 

A summary of the status of the Company’s outstanding stock options as of June 30, 2025 and December 31, 2024 and changes during the periods ending on such dates is as follows:

 

   Number of  

Weighted

Average

Exercise

  

Weighted

Average

Remaining

Contractual

  

Aggregate

Intrinsic

 
   Options   Price   Life in Years   Value 
Outstanding at December 31, 2022   238,439,167   $0.0362    1.43      
Granted   -    -           
Forfeited   (170,999,530)   0.0379           
Exercised   -    -           
Cancelled   -    -           
Outstanding – December 31, 2023   67,439,637   $0.0360    1.43      
Exercisable – December 31, 2023   41,057,753   $0.0211    1.33   $     - 
                     
Granted   -    -           
Forfeited   (1,475,000)   0.0379           
Exercised   -    -           

Expired

   

(35,295,237

)               
Cancelled   -    -           
Outstanding – June 30, 2025   30,669,400   $0.043268    1.07      
Exercisable – June 30, 2025   7,059,400   $0.0531    1.106   $- 

 

The following table summarizes information about employee stock options outstanding at June 30, 2025.

 

Range of Exercise Price  Number
outstanding
at June 30, 2025
   Weighted
average
remaining
Life
   Weighted
average
exercise
price
   Number
exercisable
at June 30, 2025
   Weighted
average
exercise
price
   Weighted
average
remaining
life
 
$ 0.0180 - $0.0225 ( Expired)   0    0.00   $0.0180    0.00   $0.0180    0.00 
$ 0.0229 - $0.0325   50,000    1.12   $0.0302    50,000   $0.0302    1.12 
$ 0.0360 - $0.0425   22,659,400    1.05   $0.0398    4,659,400   $0.0395    .92 
$ 0.0440 - $0.0531   7,960,000    1.17   $0.0531    2,350,000   $0.0530    .94 
Outstanding options   30,669,400    1.07    0.0432    7,059,400    0.0439    0.93 

 

At June 30, 2025, there was $7,059,400 of unrecognized stock option expense which may be recognized only if the full vesting requirements for these options are met.

 

At June 30, 2025, there was $79,650 of total unrecognized stock option expense, which is expected to be recognized on a straight-line basis over a weighted-average period of 1.18 years.

 

 

Warrants

 

On January 18, 2023 and February 18, 2023, the Company issued to Charles Hyatt, an aggregate of 11,428,570 units, with each unit consisting of one share of common stock and a two-year common stock purchase warrant to purchase one share of common stock at an exercise price of $0.0175 per share in consideration of $200,000.

 

A summary of the Company’s warrants as of December 31, 2024 and changes during the six months ended June 30, 2025 is presented below: 

 

   Number of  

Weighted

Average

Exercise

  

Weighted

Average

Remaining

Contractual

  

Aggregate

Intrinsic

 
   Warrants   Price   Life in Years   Value 
Outstanding – December 31, 2024   25,684,521   $0.0247    0.93   $24,000 
Granted   -                
Exercised                    
Forfeited or Expired   25,684,521                
Outstanding – June 30, 2025   -   $-           
Exercisable – June 30, 2025   -   $-        $-